In last trading session, Cytek BioSciences Inc (NASDAQ:CTKB) saw 0.59 million shares changing hands with its beta currently measuring 1.41. Company’s recent per share price level of $3.77 trading at -$0.05 or -1.31% at ring of the bell on the day assigns it a market valuation of $482.93M. That closing price of CTKB’s stock is at a discount of -102.39% from its 52-week high price of $7.63 and is indicating a premium of 13.26% from its 52-week low price of $3.27. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.61 million shares which gives us an average trading volume of 840.17K if we extend that period to 3-months.

For Cytek BioSciences Inc (CTKB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.01 in the current quarter.

Cytek BioSciences Inc (NASDAQ:CTKB) trade information

Upright in the red during last session for losing -1.31%, in the last five days CTKB remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $3.77 price level, adding 6.91% to its value on the day. Cytek BioSciences Inc’s shares saw a change of -41.91% in year-to-date performance and have moved 3.29% in past 5-day. Cytek BioSciences Inc (NASDAQ:CTKB) showed a performance of -7.60% in past 30-days. Number of shares sold short was 4.53 million shares which calculate 4.73 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6.62 to the stock, which implies a rise of 43.09% to its current value. Analysts have been projecting 5.25 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -39.26% in reaching the projected high whereas dropping to the targeted low would mean a loss of -39.26% for stock’s current value.

Cytek BioSciences Inc (CTKB) estimates and forecasts

This year revenue growth is estimated to rise 1.98% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 42.66M for the same. And 4 analysts are in estimates of company making revenue of 47.54M in the next quarter. Company posted 44.86M and 46.62M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 18.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -100.31% while estimates for its earnings growth in next 5 years are of -5.81%.

Cytek BioSciences Inc (NASDAQ:CTKB)’s Major holders

Insiders are in possession of 8.90% of company’s total shares while institution are holding 61.47 percent of that, with stock having share float percentage of 67.47%. Investors also watch the number of corporate investors in a company very closely, which is 61.47% institutions for Cytek BioSciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CTKB for having 17.07 million shares of worth $95.25 million. And as of 2024-06-30, it was holding 12.9872 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 11.75 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.9365 of outstanding shares, having a total worth of $65.54 million.

On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 6.61 shares of worth $24.92 million or 5.16% of the total outstanding shares. The later fund manager was in possession of 3.37 shares on Dec 31, 2024 , making its stake of worth around $12.69 million in the company or a holder of 2.63% of company’s stock.